Related Experiment Video
Updated: May 14, 2026
04:03
Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
Published on: September 27, 2024
Preventing COPD exacerbations with macrolides: a review and budget impact analysis
Steven Simoens1, Gert Laekeman, Marc Decramer
1Research Centre for Pharmaceutical Care and Pharmacoeconomics, KU Leuven, Onderwijs en Navorsing 2, P.O. Box 521, Herestraat 49, 3000 Leuven, Belgium. steven.simoens@pharm.kuleuven.be
Respiratory Medicine
|January 29, 2013
Summary
Long-term macrolide therapy, including azithromycin, effectively reduces exacerbations in patients with chronic obstructive pulmonary disease (COPD). This approach is a cost-saving strategy for Belgium, generating significant hospital savings.
Area of Science:
- Pulmonary Medicine
- Pharmacoeconomics
Background:
- Long-term macrolide administration at sub-bactericidal doses reduces exacerbations in chronic obstructive pulmonary disease (COPD).
- Macrolides like azithromycin, erythromycin, and clarithromycin are investigated for their long-term effectiveness and safety in COPD management.
Purpose of the Study:
- To critically review the international literature on the long-term effectiveness and safety of macrolides for COPD exacerbation prevention.
- To estimate the budget impact of preventing COPD exacerbations with azithromycin in Belgium.
Main Methods:
- A systematic literature review of controlled clinical studies was conducted using multiple databases (PubMed, EMBASE, Cochrane Library, Social Science and Citation Index).
- A budget impact analysis calculated the difference between azithromycin treatment costs and savings from reduced hospitalizations for COPD exacerbations in Belgium (GOLD stages II-IV).
Main Results:
- Literature review indicates long-term macrolide treatment (azithromycin, erythromycin, clarithromycin) is effective and safe, reducing COPD exacerbations and hospitalizations.
- Uncertainties persist regarding optimal patient selection, dosage, duration, and impact on antimicrobial resistance.
- The budget impact analysis revealed that preventing COPD exacerbations with azithromycin in Belgium is a cost-saving strategy, with annual hospital savings of €950 million exceeding azithromycin costs of €595 million.
Conclusions:
- Long-term macrolide therapy demonstrates efficacy and safety in reducing COPD exacerbations and associated hospitalizations.
- Azithromycin treatment for COPD exacerbation prevention represents a cost-saving strategy in Belgium.
- Further research is needed to optimize macrolide therapy for COPD and address concerns about antimicrobial resistance.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.